Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1629067 | 1.00 | NFE2L2 (0.42) | NFE2L2HSP90AA1PDE10AMAPK14KCNN4 | |
| SCHEMBL1628895 | 0.88 | NFE2L2 (0.42) | NFE2L2HSP90AA1MAPK14KCNN4RELA | |
| SCHEMBL1628894 | 0.88 | NFE2L2 (0.42) | NFE2L2HSP90AA1MAPK14KCNN4RELA | |
| SCHEMBL1628551 | 0.88 | CYP1A1 (0.41) | NFE2L2HSP90AA1MAPK14KCNN4RELA | |
| SCHEMBL1628547 | 0.88 | CYP1A1 (0.41) | NFE2L2HSP90AA1MAPK14KCNN4RELA | |
| SCHEMBL1630512 | 0.86 | NFE2L2 (0.46) | NFE2L2HSP90AA1MAPK14KCNN4RELA | |
| SCHEMBL1630510 | 0.86 | NFE2L2 (0.46) | NFE2L2HSP90AA1MAPK14KCNN4RELA | |
| SCHEMBL1631539 | 0.86 | CYP1A1 (0.43) | NFE2L2HSP90AA1MAPK14KCNN4LMNA | |
| SCHEMBL1630458 | 0.86 | HSP90AA1 (0.44) | NFE2L2HSP90AA1PDE10AMAPK14KCNN4 | |
| SCHEMBL1630462 | 0.86 | HSP90AA1 (0.44) | NFE2L2HSP90AA1PDE10AMAPK14KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776346-B1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-7932401-B2 | Heat Shock Protein 90 (HSP90) inhibitors; 5-(2-hydroxy-4-methoxyphenyl)-1-(3-nitrophenyl)-1H-pyrazole for example; antitumor agent, viral diseases, transplant rejection, cystic fibrosis, angiogenesis inhibition, infectious, autoimmune, or inflammatory diseases, ischemia, chemotherapy cytoprotectant | MERCK PATENT GMBH (DE) | 2011-04-26 | — | — | US | disclosed |
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | MERCK PATENT GMBH (DE) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085904-A1 | 1,5-Diphenylpyrazoles | HSP90AB1, HSP90AA1, HSP90AB2P | NFE2L2 1367/4885HSP90AA1 2/4885PDE10A 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.